4,5,6,7-四氢噻吩[3,2-C]吡啶-2-羧酸 | 116118-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: 4,5,6,7-四氢噻吩[3,2-C]吡啶-2-羧酸
• 中文别名: 4,5,6,7-四氢噻吩3,2-C吡啶-2-羧酸
• 英文名称: 4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylic acid
• 英文别名: 4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-carboxylic acid；4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-5-ium-2-carboxylate
• CAS: 116118-98-0
• 化学式: C₈H₉NO₂S
• mdl: MFCD08696382
• 分子量: 183.231
• InChiKey: OEYJTWUFGQRSOD-UHFFFAOYSA-N

物化性质

• 熔点：
  277 °C (decomp)
• 沸点：
  401.6±45.0 °C(Predicted)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  77.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放在2-8°C的环境中，应避免光照，保持干燥并密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4,5,6,7-Tetrahydrothieno[3,2-c]pyridine-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4,5,6,7-Tetrahydrothieno[3,2-c]pyridine-2-carboxylic acid
CAS number: 116118-98-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9NO2S
Molecular weight: 183.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢噻吩[3,2-C]吡啶-2-羧酸 在 氢溴酸 作用下， 以95%的产率得到4,5,6,7-四氢噻吩并[3.2-c]吡啶
  参考文献：
  名称：

  Tetrahydrothienopyridylbutyl-tetrahydrobenzindoles: New Selective Ligands of the 5-HT7 Receptor

  摘要：

  The synthesis and the affinity for the 5-HT7 receptor and other receptors of a novel series of fused-ring tetrahydropyridine derivatives are described. Some of the compounds showed high affinity for the 5-HT7 receptor. Tetrahydrothienopyridylbutyl-tetrahydrobenzindoles 5d and 5h are potent ligands for the 5-HT7 receptor, with high selectivity over the 5-HT2 receptor and other receptors. These compounds should be useful tools for clarifying the biological role of the 5-HT7 receptor. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00485-7
• 作为产物：
  描述：

  在 氢氧化钾 作用下， 生成 4,5,6,7-四氢噻吩[3,2-C]吡啶-2-羧酸
  参考文献：
  名称：

  Tetrahydrothienopyridylbutyl-tetrahydrobenzindoles: New Selective Ligands of the 5-HT7 Receptor

  摘要：

  The synthesis and the affinity for the 5-HT7 receptor and other receptors of a novel series of fused-ring tetrahydropyridine derivatives are described. Some of the compounds showed high affinity for the 5-HT7 receptor. Tetrahydrothienopyridylbutyl-tetrahydrobenzindoles 5d and 5h are potent ligands for the 5-HT7 receptor, with high selectivity over the 5-HT2 receptor and other receptors. These compounds should be useful tools for clarifying the biological role of the 5-HT7 receptor. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00485-7

文献信息

• [EN] MASP-2 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MASP-2 ET PROCÉDÉS D'UTILISATION
  申请人：OMEROS CORP

  公开号：WO2021113686A1

  公开（公告）日：2021-06-10

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物以及制备和使用这些化合物的方法。
• Compound with platelet aggregation inhibitor activity
  申请人：Meiji Seika Kabushiki Kaisha

  公开号：US05594004A1

  公开（公告）日：1997-01-14

  A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: ##STR1## wherein R.sup.1 represents a group --W--(CH.sub.2).sub.i --COOR.sup.3, R.sup.2 represents a hydrogen atom or a group --W--(CH.sub.2).sub.i --COOR.sup.3 or --OR.sup.4, X represents --CH.dbd. or --N.dbd., Y represents (i) a group --(CO).sub.k --N(R.sup.5)--Z--, wherein Z represents a bond or a group --(CH.sub.2).sub.m --CO-- or a group --(CH.sub.2).sub.m --CHR.sup.6 --, (ii) a group --(CH.sub.2).sub.m --N(R.sup.5)--(CO).sub.k --, or (iii) a group --(CO).sub.k -Het, wherein Het represents a five- or six-membered heterocyclic ring comprising a nitrogen atom, A represents (i) the following groups (III) or (IV) ##STR2## B represents a bond, C.sub.1-6 alkylene or C.sub.2-6 alkenylen.

  公开了一种由通式（I）表示的化合物及其在制约血小板凝聚方面具有作用的药用可接受盐和溶剂：其中R.sup.1代表一个基团--W--(CH.sub.2).sub.i --COOR.sup.3，R.sup.2代表氢原子或基团--W--(CH.sub.2).sub.i --COOR.sup.3或--OR.sup.4，X代表--CH.dbd.或--N.dbd.，Y代表（i）一个基团--(CO).sub.k --N(R.sup.5)--Z--，其中Z代表一个键或一个基团--(CH.sub.2).sub.m --CO--或一个基团--(CH.sub.2).sub.m --CHR.sup.6 --，（ii）一个基团--(CH.sub.2).sub.m --N(R.sup.5)--(CO).sub.k --，或（iii）一个基团--(CO).sub.k-Het，其中Het代表一个含氮原子的五元或六元杂环环，A代表（i）以下基团（III）或（IV），B代表一个键，C.sub.1-6烷基或C.sub.2-6烯基。
• Tetrahydro-fused pyridines as histone deacetylase inhibitors
  申请人：Maier Thomas

  公开号：US08440830B2

  公开（公告）日：2013-05-14

  The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases.

  式(I)的化合物中，环D和环E共同形成由式(II)、(III)、(IV)、(V)、(VI)和(VII)所选择的融合环系统，这些化合物的盐是组蛋白去乙酰化酶的新型有效抑制剂。
• NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Maier Thomas

  公开号：US20110021494A1

  公开（公告）日：2011-01-27

  The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases.

  式(I)的化合物，其中环D和环E共同形成选自式(II)，(III)，(IV)，(V)，(VI)，(VII)的融合环系统，以及这些化合物的盐是组蛋白去乙酰化酶的新颖有效抑制剂。
• TETRAHYDROBENZINDOLE DERIVATIVES
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1057814A1

  公开（公告）日：2000-12-06

  This invention creates compounds represented by the following formula (1) which, alone or as a plurality of them simultaneously, act upon serotonin receptors, and thereby provides pharmaceutical compositions that contain these compounds and are useful for the treatment or prevention of diseases which are considered to be induced by the abnormality of central and peripheral serotonin controlling functions. In the formula, R1 is a hydrogen atom, a lower alkyl group or an aralkyl group; R2 is a hydrogen atom or a specified substituent; n is an integer of 2 to 6; and α is the following formula (a), (b), (c), (d) or (e). In formulae (a) and (b), R3 is a hydrogen atom or a specified substituent; X is NR10, NCONR11R12, S, SO, SO2 or O; R10 is a hydrogen atom or a specified substituent; R11 and R12 is independently a hydrogen atom or a lower alkyl; Y is a methylene group or a carbonyl group. In formula (c), R4 is a hydrogen atom or a specified substituent; R5 is a hydrogen atom or a specified substituent; k is 0 or an integer of 1 to 3; m is 0 or an integer of 1 to 3; each of A and B is a group which forms a specified ring via a double bond; k + m is an integer of 1 to 3. In formulae (d) and (e), R4 is as defined above; G is CH2, S, O or C=O; D is CH or N; p is an integer of 1 to 3; each of E and J is a group which forms a benzene ring or a pyridine ring via a double bond; R6 and R7 is independently a hydrogen atom or a lower alkyl or the like specified substituent.

  本发明创造了由下式(1)表示的化合物，这些化合物单独或多个同时作用于血清素受体，从而提供了含有这些化合物的药物组合物，这些组合物可用于治疗或预防被认为是由中枢和外周血清素控制功能异常诱发的疾病。 式中，R1 是氢原子、低级烷基或芳烷基；R2 是氢原子或特定取代基；n 是 2 至 6 的整数；α 是下式 (a)、(b)、(c)、(d) 或 (e)。 在式(a)和(b)中，R3 是氢原子或特定取代基；X 是 NR10、NCONR11R12、S、SO、SO2 或 O；R10 是氢原子或特定取代基；R11 和 R12 独立地是氢原子或低级烷基；Y 是亚甲基或羰基。在式(c)中，R4 是氢原子或特定取代基；R5 是氢原子或特定取代基；k 是 0 或 1 至 3 的整数；m 是 0 或 1 至 3 的整数；A 和 B 各自是通过双键形成特定环的基团；k + m 是 1 至 3 的整数。在式(d)和(e)中，R4 如上定义；G 是 CH2、S、O 或 C＝O；D 是 CH 或 N；p 是 1 至 3 的整数；E 和 J 各自是通过双键形成苯环或吡啶环的基团；R6 和 R7 独立地是氢原子或低级烷基或类似的指定取代基。